2022 年加拿大接受尼马瑞韦/利托那韦（PaxlovidTM）治疗者的特征和临床疗效：一项描述性队列研究

{"title":"2022 年加拿大接受尼马瑞韦/利托那韦（PaxlovidTM）治疗者的特征和临床疗效：一项描述性队列研究","authors":"Nadine Sicard, Susan Squires, Muhammad Mullah, Peter Daley","doi":"10.14745/ccdr.v49i10a05","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":33496,"journal":{"name":"Canada Communicable Disease Report","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characteristics and clinical outcomes of nirmatrelvir/ritonavir (PaxlovidTM) recipients in Canada, 2022: a descriptive cohort study\",\"authors\":\"Nadine Sicard, Susan Squires, Muhammad Mullah, Peter Daley\",\"doi\":\"10.14745/ccdr.v49i10a05\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":33496,\"journal\":{\"name\":\"Canada Communicable Disease Report\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canada Communicable Disease Report\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14745/ccdr.v49i10a05\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canada Communicable Disease Report","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14745/ccdr.v49i10a05","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}